Could sotatercept help PAH patients breathe easier?
NCT ID NCT07140484
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times
Summary
This study tests whether the drug sotatercept can improve how well the lungs transfer oxygen in people with pulmonary arterial hypertension (PAH). Twenty-seven adults with PAH will receive the drug every 21 days for 29 weeks and undergo lung function tests, heart ultrasounds, and blood draws. The goal is to see if the drug helps recruit more lung blood vessels during exercise, which could ease breathing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinical Physiology Laboratory
RECRUITINGEdmonton, Alberta, T6G2R3, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill ease the strain of pulmonary arterial hypertension?
- Could a gut bacteria transplant ease a rare lung disease?
- Can a diabetes drug help the heart burn fuel better in pulmonary hypertension?
- Can a smartwatch replace the clinic walk test for lung disease patients?
- Blood particles may reveal hidden clues to scleroderma complications
- Heart scans may soon replace Needle-Based catheter tests